Patents by Inventor Jacob Michael Vogan
Jacob Michael Vogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124905Abstract: Provided is a nucleic acid comprising a recombinant bacterial or archaeal geranyl pyrophosphate synthase (GPPS) gene, codon optimized for production in yeast. Also provided is a yeast cell comprising an expression cassette comprising the above nucleic acid. Additionally provided is a method of producing a terpene or cannabinoid in a yeast, the method comprising incubating the above yeast cell in a manner sufficient to produce the terpene or cannabinoid.Type: ApplicationFiled: January 26, 2022Publication date: April 18, 2024Inventors: Erin Marie SCOTT, Kirsten TANG, Jacob Michael VOGAN
-
Publication number: 20230383314Abstract: Provided is an engineered olivetolic acid cyclase (OAC) enzyme derived from a microorganism or non-Cannabis plant, wherein the enzyme catalyzes cyclization of a polyketide (I) into a resorcyclic acid derivative (II), where R1=CH3, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, or (CH2)6CH3 Also provided is nucleic acids encoding the above OAC enzyme, expression cassettes comprising those nucleic acids, and recombinant microorganisms comprising those expression cassettes that express the OAC enzyme encoded therein. Additionally provided is a method of converting a polyketide (I) into a resorcyclic acid derivative (II) comprising contacting the polyketide with the above-identified OAC enzyme in a manner and for a time sufficient to convert the polyketide (I) into the resorcyclic acid derivative (II).Type: ApplicationFiled: May 27, 2022Publication date: November 30, 2023Applicant: CB Therapeutics, Inc.Inventors: Erin Marie Scott, Jacob Michael Vogan, Tyler Huelsman
-
Publication number: 20230313154Abstract: Provided is a nucleic acid comprising a sequence encoding a prenyltransferase (PT) gene or its complement, codon optimized for production in a microorganism or a plant. Also provided is a yeast expression cassette comprising the above nucleic acid. Additionally provided is a non-naturally occurring prenyltransferase (PT) comprising an amino acid sequence having at least 90% amino acid sequence identity or conservative amino acid substitutions to the amino acid sequences encoded by the above nucleic acid. Further provided is a recombinant microorganism or plant expressing a PT encoded by the above nucleic acid. Additionally provided is a method of catalyzing the condensation of a polyprenol diphosphate and an alkylresorcinol or alkylresorcyclic acid to yield a cannabinoid.Type: ApplicationFiled: July 16, 2021Publication date: October 5, 2023Applicant: CB THERAPEUTICS, INC.Inventors: Erin Marie Scott, Jacob Michael Vogan, Tyrone Jacob Yacoub
-
Publication number: 20230242919Abstract: Provided are non-naturally occurring nucleic acids comprising a sequence encoding an enzyme or regulatory protein in tryptamine metabolism. Also provided are a recombinant microorganisms expressing the enzyme or regulatory protein. Methods of expressing the enzyme or regulatory protein are additionally provided.Type: ApplicationFiled: June 4, 2021Publication date: August 3, 2023Applicant: CB Therapeutics, Inc.Inventors: Laura Flatauer Peiffer, Jacob Michael Vogan, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
-
Publication number: 20220389467Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.Type: ApplicationFiled: August 1, 2022Publication date: December 8, 2022Applicant: CB Therapeutics, INC.Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
-
Publication number: 20220298533Abstract: Provided is a method of modifying a first cannabinoid into a second cannabinoid or a non-cannabinoid. The method comprises combining the first cannabinoid with an enzyme that can modify the first cannabinoid into the second cannabinoid or non-cannabinoid under conditions where the first cannabinoid is modified into the second cannabinoid or non-cannabinoid. Also provided is a non-naturally occurring enzyme that can modify a first cannabinoid into a second cannabinoid or a non-cannabinoid. A nucleic acid encoding that enzyme is additionally provided. Further provided is a non-naturally occurring nucleic acid that encodes an enzyme having the enzymatic activity of the above non-naturally occurring enzyme. An expression cassette comprising that nucleic acid is additionally provided. A cell comprising the above expression cassette is further provided. Also provided is a plant expression cassette comprising the above-identified nucleic acid.Type: ApplicationFiled: March 22, 2022Publication date: September 22, 2022Applicant: CB Therapeutics, Inc.Inventors: Erin Marie Scott, Jacob Michael Vogan
-
Patent number: 11441164Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.Type: GrantFiled: November 16, 2020Date of Patent: September 13, 2022Assignee: CB THERAPEUTICS, INC.Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
-
Publication number: 20210388035Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.Type: ApplicationFiled: June 16, 2021Publication date: December 16, 2021Applicant: CB Therapeutics, Inc.Inventors: Erin Marie Scott, Jacob Michael Vogan
-
Patent number: 11041002Abstract: The methods and systems disclose enzymes that function to import malonic acid or malonates into a cell. The enzymes increase the output of precursor molecules by enriching certain pathways in the cell. The precursor molecules can be converted to cannabinoids. The enzymes are a family of proteins which have a majority of common alignments.Type: GrantFiled: September 3, 2019Date of Patent: June 22, 2021Assignee: CB THERAPEUTICS, INC.Inventors: Erin Marie Scott, Jacob Michael Vogan
-
Patent number: 11028417Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: GrantFiled: August 27, 2019Date of Patent: June 8, 2021Assignee: CB THERAPEUTICS, INC.Inventors: Sher Ali Butt, Jacob Michael Vogan
-
Publication number: 20210147888Abstract: The systems and methods herein include engineering a host to produce psilocybin using engineered enzymes, genetic changes, and exogenous psilocybin precursor addition (e.g., addition of L-tryptophan to a growing culture of a psilocybin producing recombinant host strain). The process occurs in genetically engineered host cell(s) that can produce psilocybin.Type: ApplicationFiled: November 16, 2020Publication date: May 20, 2021Applicant: CB Therapeutics, INC.Inventors: Jacob Michael Vogan, Laura Flatauer Peiffer, James Lee Wade, Tyrone Jacob Yacoub, Kirsten Tang, Rachel Nadine Burnett
-
Patent number: 10988785Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: GrantFiled: August 27, 2019Date of Patent: April 27, 2021Assignee: CB THERAPEUTICS, INC.Inventors: Sher Ali Butt, Jacob Michael Vogan
-
Patent number: 10982243Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular, modified, or synthetic gene(s) of select enzymes that are processed and inserted into an expression system (for example, a vector, cosmid, BAC, YAC, phage) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: GrantFiled: August 28, 2019Date of Patent: April 20, 2021Assignee: CB THERAPEUTICS, INC.Inventors: Sher Ali Butt, Jacob Michael Vogan
-
Publication number: 20200063170Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the Cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: ApplicationFiled: August 28, 2019Publication date: February 27, 2020Applicant: CB Therapeutics, INC.Inventors: SHER ALI BUTT, JACOB MICHAEL VOGAN
-
Publication number: 20200063171Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: ApplicationFiled: August 28, 2019Publication date: February 27, 2020Applicant: CB Therapeutics, INC.Inventors: SHER ALI BUTT, JACOB MICHAEL VOGAN
-
Patent number: 10435727Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the Cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: GrantFiled: September 28, 2017Date of Patent: October 8, 2019Inventors: Sher Ali Butt, Jacob Michael Vogan
-
Publication number: 20180155748Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: ApplicationFiled: September 28, 2017Publication date: June 7, 2018Inventors: SHER ALI BUTT, JACOB MICHAEL VOGAN
-
Publication number: 20160298151Abstract: The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.Type: ApplicationFiled: April 11, 2016Publication date: October 13, 2016Inventors: Sher Ali Butt, Jacob Michael Vogan